Pfizer Q1 Revenue Rises 5.7% to $14.5B, Acquisitions Drive $3.1B Growth
Pfizer generated $14.5 billion in Q1 revenue, a 5.7% year-over-year increase that topped estimates by $649 million. Acquired products contributed $3.1 billion with 22% operational growth and Vyndamax exclusivity extension through FY31 cuts projected patent-cliff exposure from $17 billion to about $14–15 billion.
1. Q1 Financial Results
Pfizer posted $14.5 billion in first-quarter revenue, up 5.7% year-over-year, exceeding consensus estimates by $649 million. The growth reflected solid performance across core drug portfolios and offset declines in pandemic-related sales.
2. Acquisition-Fueled Growth
Revenue from acquired products reached $3.1 billion, delivering a 22% operational increase. This uplift was driven by strategic bolt-on deals that enhanced Pfizer’s portfolio with innovative therapies.
3. Patent Cliff Mitigation
An exclusivity extension for Vyndamax into fiscal 2031 reduces Pfizer’s patent-cliff exposure by roughly $2–3 billion, bringing projected at-risk revenue down from $17 billion to about $14–15 billion over the next few years.